Vorasidenib: A narrative drug review
Isocitrate dehydrogenase (IDH) mutations (IDH1 and IDH2) are observed in malignancies such as low-grade gliomas, acute myeloid leukemia, cholangiocarcinoma, and chondrosarcoma. Vorasidenib is a targeted therapy for IDH-mutant gliomas that significantly delays disease progression and the need for add...
Wedi'i Gadw mewn:
| Prif Awduron: | , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Wolters Kluwer Medknow Publications
2025-10-01
|
| Cyfres: | Cancer Research, Statistics, and Treatment |
| Pynciau: | |
| Mynediad Ar-lein: | https://journals.lww.com/10.4103/crst.crst_46_25 |
| Tagiau: |
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|